COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications
Research output: Contribution to journal › Review › Research › peer-review
Standard
COVID-19 associated atrial fibrillation : Incidence, putative mechanisms and potential clinical implications. / Gawalko, Monika; Kaplon-Cieslicka, Agnieszka; Hohl, Mathias; Dobrev, Dobromir; Linz, Dominik.
In: IJC Heart and Vasculature, Vol. 30, 100631, 2020.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 associated atrial fibrillation
T2 - Incidence, putative mechanisms and potential clinical implications
AU - Gawalko, Monika
AU - Kaplon-Cieslicka, Agnieszka
AU - Hohl, Mathias
AU - Dobrev, Dobromir
AU - Linz, Dominik
PY - 2020
Y1 - 2020
N2 - Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AB - Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients. (C) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
KW - Anticoagulation
KW - Arrhythmia
KW - Inflammasome
KW - Remote monitoring
KW - Thromboembolic risk
KW - OBSTRUCTIVE RESPIRATORY EVENTS
KW - CRITICALLY-ILL PATIENTS
KW - INFLAMMATION
KW - PROMOTES
KW - RECEPTOR
KW - OUTCOMES
KW - ACE2
KW - ARRHYTHMIAS
KW - DYSFUNCTION
KW - AMIODARONE
U2 - 10.1016/j.ijcha.2020.100631
DO - 10.1016/j.ijcha.2020.100631
M3 - Review
C2 - 32904969
VL - 30
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
SN - 2352-9067
M1 - 100631
ER -
ID: 251588892